Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Barclays

Stock analysts at Barclays assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a note issued to investors on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $923.00 price target on the biopharmaceutical company’s stock. Barclays‘s price target suggests a potential upside of 20.66% from the stock’s current price.

REGN has been the topic of several other reports. HSBC initiated coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective on the stock. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday. Finally, Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Stock Down 2.9%

Shares of REGN opened at $764.93 on Friday. The firm has a 50 day simple moving average of $771.31 and a two-hundred day simple moving average of $686.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The company has a market cap of $80.87 billion, a P/E ratio of 18.41, a P/E/G ratio of 2.12 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $12.07 EPS. The company’s revenue was up 2.5% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pure Financial Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 35.4% in the fourth quarter. Pure Financial Advisors LLC now owns 497 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 130 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of Regeneron Pharmaceuticals by 10.4% in the fourth quarter. Rehmann Capital Advisory Group now owns 2,371 shares of the biopharmaceutical company’s stock worth $1,834,000 after acquiring an additional 223 shares during the period. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Bank of Hawaii increased its position in Regeneron Pharmaceuticals by 2.5% during the 4th quarter. Bank of Hawaii now owns 1,049 shares of the biopharmaceutical company’s stock valued at $810,000 after purchasing an additional 26 shares during the period. Finally, Reflection Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $108,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.